Table 1.
Baseline demographic and clinical characteristics of 565 Canary Prostate Active Surveillance Study (PASS) participants with diet data.
| Health Eating Index HEI-(2015) Score | Alternative Mediterranean Diet Score | DASH Diet Score | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Diet Quality Index, range | 43.5 - 65.9 | 66.0 – 74.5 | 74.5 - 92.7 | 0 - 3 | 4-5 | 6 - 9 | 12 - 22 | 23 - 27 | 28 - 37 |
| n | 188 | 188 | 188 | 205 | 211 | 148 | 195 | 186 | 183 |
| Age, years, median [IQR] | 64 [60,67] | 64 [60, 67] | 64 [59, 67] | 64 [60, 67] | 63 [58, 68] | 63 [57, 66] | 63 [58, 67] | 64 [59, 68] | 63 [58, 67] |
| BMI, kg/m2, median [IQR] | 28.2 [25.6,31.0] | 27.2 [24.9, 29.8] | 25.8 [23.7, 28.1] | 27.3 [24.8, 30.3] | 27.2 [25.2, 29.8] | 26.1 [24.0, 28.8] | 27.9 [25.6, 31.1] | 26.9 [24.8, 29.4] | 26.1 [24.2, 28.6] |
| Race, n (%) | |||||||||
| Black | 9 (5) | 10 (5) | 7 (4) | 12 (6) | 9 (4) | 5 (3) | 15 (8) | 3 (1) | 8 (5) |
| White | 168 (89) | 176 (92) | 171 (91) | 182 (88) | 115 (55) | 193 (93) | 168 (86) | 175 (94) | 169 (92) |
| Other | 12 (6) | 5 (3) | 10 (5) | 12 (6) | 52 (25) | 6 (4) | 12 (6) | 9 (5) | 6 (3) |
| Family history of Prostate Cancer, n (%) | |||||||||
| Yes | 46 (24) | 46 (24) | 51 (27) | 47 (23) | 56 (27) | 40 (27) | 52 (27) | 40 (21) | 51 (28) |
| No | 131 (69) | 131 (70) | 123 (65) | 145 (70) | 140 (66) | 100 (68) | 129 (66) | 132 (71) | 124 (68) |
| Unknown | 12 (6) | 11 (6) | 14 (8) | 14 (7) | 15 (7) | 8 (5) | 14 (7) | 15 (8) | 8 (4) |
| Smoking status, n (%) | |||||||||
| Ever | 94(50) | 117 (42) | 57 (36) | 99 (48) | 88 (41) | 54 (36) | 104 (48) | 80 (42) | 78 (38) |
| Never | 95 (50) | 108 (58) | 121 (64) | 107 (52) | 123 (59) | 97 (64) | 101 (52) | 107 (58) | 116 (63) |
| Diabetes, n (%) | |||||||||
| Yes | 19 (10) | 12 (6) | 7 (4) | 20 (8) | 16 (8) | 2 (1) | 17 (8) | 15 (8) | 6 (3) |
| No | 189 (92) | 176 (94) | 203 (97) | 186 (91) | 195 (92) | 146 (99) | 198 (92) | 172 (92) | 200 (97) |
| Energy Intake, kcal, median [IQR] | |||||||||
| 2132 [1480, 2727] | 2,126 [1724, 2658] | 2021 [1628, 2540] | 1820 [1364, 2310] | 2,172 [1,757, 2,672] | 2400 [1930, 2876] | 2037 [1534, 2632] | 2,078 [1599, 2,616] | 2172 [1757, 2656] | |
| Alcohol, grams, median [IQR] | |||||||||
| 2.9 [0.04, 16.1] | 11.1 [2.0, 22.2] | 10.8 [2.0, 23.9] | 3.8 [0, 20.0] | 10.0 [0.9, 20.9] | 9.3 [2.8, 20.2] | 7.5 [0.7, 21.5] | 9.2 [1.3, 21.7] | 8.3 [1.0, 19.3] | |
| Clinical Characteristics | |||||||||
| Prostate size, cc, median [IQR] | |||||||||
| 38.4 [28.2, 52.5] | 42.3 [28.9,57.8] | 39.6 [28.3, 57.0] | 38.3 [28.7, 55.7] | 42.2 [27.9, 59.0] | 39.2 [28.8, 48.5] | 38.0 [28.3, 53.8] | 44.4 [29.8, 59.2] | 40.0 [27.5, 52.8] | |
| % of cores positive for cancer, mean (SD) | |||||||||
| 14.5 (9.5) | 14.1 (9.1) | 14.1 (8.6) | 14.5 (9.4) | 14.0 (9.0) | 14.3 (8.9) | 14.4 (9.8) | 14.7 (9.3) | 13.6 (7.9) | |
| PSA, median [IQR] | 4.7 [3.5, 5.9] | 4.7 [3.4, 6.3] | 4.5 [3.5, 6.0] | 4.8 [3.6, 6.3] | 4.6 [3.6, 6.1] | 4.5 [3.2, 5.7] | 4.8 [3.6, 6.2] | 4.5 [3.5, 6.0] | 4.6 [3.2, 6.0] |
| Length of PASS follow-up, yrs, median [IQR] | |||||||||
| 7.6 [6.3, 9.3] | 7.7 [6.6, 9.5] | 8.3 [6.6, 9.9] | 7.8 [6.7, 9.4] | 8.1 [6.4, 9.8] | 7.7 [6.5, 9.5] | 7.9 [6.4, 9.4] | 7.7 [6.5, 9.4] | 8.1 [6.4, 9.8] | |
| Time between diagnosis and enrollment, yrs, median [IQR] | |||||||||
| 0.6 [0.3, 1.2] | 0.6 [0.4, 1.3] | 0.6 [0.4, 1.3] | 0.6 [0.3, 1.1] | 0.6 [0.4, 1.4] | 0.7 [0.4, 1.5] | 0.6 [0.3, 1.2] | 0.6 [0.3, 1.3] | 0.6 [0.4, 1.4] | |
| Gleason Grade Group | |||||||||
| GG1 | 168 (90) | 173 (92) | 174 (93) | 189 (92) | 190 (90) | 136 (93) | 180 (93) | 168 (90) | 167 (92) |
| GG2 | 19 (10) | 15 (8) | 13 (7) | 16 (8) | 20 (10) | 11 (8) | 14 (7) | 18 (10) | 15 (8) |
| Clinical T Stage, n (%) | |||||||||
| T1 | 166 (88) | 171 (91) | 163 (87) | 184 (89) | 187 (89) | 129 (87) | 176 (90) | 165 (88) | 159 (87) |
| T2 | 19 (10) | 17 (9) | 25 (13) | 22 (11) | 24 (11) | 19 (13) | 19 (10) | 22 (12) | 24 (13) |